KALA BIO, Inc.
KALA
NASDAQ·Healthcare·Biotechnology·Mkt cap $9.8M
$0.45
▲ +4.29%
P/E
—
Mkt Cap
$9.8M
52-Wk Range
$0.40–$95.50
52-Week Range
$0.40 - $95.50
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 99.4% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary mucus penetrating particle (MPP) technology platform
- World-class founding team with deep biotech expertise and academic credibility
- Exclusive focus on high-value ophthalmic market with limited competition
- Patent-protected intellectual property with strong barriers to entry
Bear Case
1 risk
- Low volatility (beta -2.3).
Growth
Stable outlook
Clinical trial advancement and FDA approvals for pipeline candidates
Value
Valuation data unavailable
Momentum
Falling
-75.9% over 3m
Quality
Loss-making
Weak fundamentals - proceed with caution
Dividend
None
No dividend
Smart-money signal
Who's buying KALA right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 10, 2026
AUG 19, 2026
Reported EPS of -$21.32 vs -$6.00 consensus (-255.3% surprise).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-255.3%
Revenue trend · last 8Q
—
—
—
—
—
—
—
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$0
$0
$0
$0
$0
$0
$0
Margins · last 8Q
No margin history available.
Wall Street consensus
Analyst coverage
Live ratings and price targets aggregated across covering analysts.
vs Industry
How KALA stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.